<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8"><gtr:id>D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8</gtr:id><gtr:name>University of Ottawa</gtr:name><gtr:address><gtr:line1>550 Cumberland</gtr:line1><gtr:line4>Ottawa</gtr:line4><gtr:line5>Ontario K1N 6N5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Division of Cancer Biology</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8"><gtr:id>D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8</gtr:id><gtr:name>University of Ottawa</gtr:name><gtr:address><gtr:line1>550 Cumberland</gtr:line1><gtr:line4>Ottawa</gtr:line4><gtr:line5>Ontario K1N 6N5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2CD45E6C-C459-4FD5-AE2D-54F26B89B0AC"><gtr:id>2CD45E6C-C459-4FD5-AE2D-54F26B89B0AC</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Rigby</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0401199"><gtr:id>1F7C4DE9-7C6F-45B3-ACE6-0EF218DC56D9</gtr:id><gtr:title>Molecular Mechanisms of Skeletal Muscle Specification and Differentiation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0401199</gtr:grantReference><gtr:abstractText>One of the major scientific achievements of the past century has been the completion of the human genome project, which has revealed that the complexity of the human body comes from the activity of a mere 30,000 genes. These are small phrases in a book entitled: How to construct a human body and make it work . All the cells in our bodies have the same genes and if eyes are different from hands it is because those genes that say how to make hands are not active in the eyes and vice versa. Nevertheless, knowing the sequence of all our genes is not enough to understand how a body is made, because we still do not know how it is decided when and where to switch on (or off) a gene or set of genes in order to produce a particular organ or tissue. Answering this question is one of the biggest scientific challenges ahead of us. Our research concentrates on how a group of embryonic cells takes the decision to become muscle rather than bone or skin. The genes that turn those cells into muscle are known, and in our previous research we have located the switches for these genes. The next steps are to find out what operates these switches, why and how a switch only works on a single gene, even if other genes are also close by, and why some muscles need multiple switches.
Although we concentrate on muscle development, the answers to some of these questions are likely to apply to other genes, and thus help us understand how a human body is made. Understanding how to make a muscle will help scientists and doctors to develop, in the future, therapies oriented towards the repair or re-growth of injured or diseased muscles, by using a few cells from the patient or a relative and instructing them to re-create the missing structure.</gtr:abstractText><gtr:technicalSummary>The Myogenic Regulatory Factors are a family of transcription factors essential for the determination and differentiation of skeletal muscle during embryonic development. The genes encoding two members of this family, Mrf4 and Myf5, are closely linked and have overlapping but distinct, highly dynamic expression patterns. We have studied the transcriptional regulation of Mrf4 and Myf5 in transgenic mice and shown that a multitude of interdigitated enhancers regulate gene activation at different times and anatomical locations. Despite this complex architecture, the enhancers recognize their respective core promoters, and we have shown that a series of equilibrium-states between promoter-capable sequences and the enhancers is required to drive correct expression and transcriptional initiation. We intend to further investigate the regulation of this locus at different levels of complexity, including a full characterization of the transcription factors binding to some individual enhancers, understanding the molecular mechanisms behind enhancer cooperation during cranio-facial muscle development and the underlying mechanisms of the promoter-enhancer equilibria that we have identified. We will also investigate how different subsets of precursors contribute to mature muscles. For the characterization of enhancers and putative transcription binding sites, we will use a combination of the newest bioinformatics tools for the comparative analysis of multiple genomes (MultiPIP Maker, mVISTA and rVISTA) and electrophoretic mobility shift assays (EMSA) with protein extracts obtained from whole embryos. In some cases, the biological importance of particular binding sites will be analysed by transfection of reporter constructs into C2C12 cells, but most of our work depends on the use of transgenic mice. To analyse the contribution of each enhancer to the full pattern of expression, we will delete them individually or in combination, or introduce single point mutations into our existing BAC constructs using linear recombination in E. coli, with which we are very experienced. In the anatomical studies we will use serial sections for anatomical reconstruction, apply the laacZ method for tracing as well as novel methods involving Cre-lox technology, which we are currently developing, which will allow us to follow individual cells and their descendants well beyond the time of enhancer activation. The work proposed is unlikely to generate commercially exploitable results in the short to medium term. It may contribute to the development of gene delivery vehicles for skeletal muscle and regimes for increasing the mobilisation of satellite and stem cells in repair and regeneration.</gtr:technicalSummary><gtr:fund><gtr:end>2010-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1551180</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ottawa</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Activation of Myf5 in satellite cells</gtr:description><gtr:id>27DE71E6-19C3-4FFC-A464-ADD5AF4047F3</gtr:id><gtr:impact>We have shown that Pax7 activates Myf5 expression in quiescent satellite cells. We have shown that the enhancer containing a strong Pax7 binding site is essential for this expression. We are writing a joint paper at the moment</gtr:impact><gtr:outcomeId>NnhUyFSZz7H-1</gtr:outcomeId><gtr:partnerContribution>Provided data on ChIP-seq for pax3 and Pax7</gtr:partnerContribution><gtr:piContribution>We have analysed the enhancer involved in transgenic animals</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Max Planck Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max Planck Institute for Heart and Lung Research</gtr:department><gtr:description>Myf5 Function in Satellite Cell Survival</gtr:description><gtr:id>B720BA47-648F-40D2-BAB7-526E986D0597</gtr:id><gtr:impact>We have shown that Myf5 is involved in the survival of skeletal muscle satellite cells (PMID: 17495111)</gtr:impact><gtr:outcomeId>41ED20D09B2-1</gtr:outcomeId><gtr:partnerContribution>We have received knock-out animals and produced a publication</gtr:partnerContribution><gtr:piContribution>We have provided transgenic lines</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>EC FP6 Collaborative Projects</gtr:department><gtr:description>MYORES Network of Excellence</gtr:description><gtr:id>86DC6F05-BB91-40B0-9B5E-9F0B32352F6E</gtr:id><gtr:impact>We have been able to identify the TEAD family of transcription factors acting upstream of the Mrf4/Myf5 locus. We have found an unexpected and novel function for Mrf4 in adult muscle homeostasis. A paper describing this research is currently under review in the scientific journal Developmental Biology</gtr:impact><gtr:outcomeId>A806F91D70D-1</gtr:outcomeId><gtr:partnerContribution>The Network has provided a framework of information exchange and the ability to use the many common research platforms belonging to the network. The chicken electroporation platform has been particularly useful to our research as we have made extensive use of it in the analyses of regulatory elements for the mrf4/Myf5 locus. We have also made extensive use of the Adult Muscle Electroporation Platform (University of Padova) to unravel the function of Mrf4 in adult musculature.</gtr:partnerContribution><gtr:piContribution>We have provided reagents to many members of the Network, exchange of unpublished data and training on laboratory techniques to junior members.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pump Priming Grant</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>1F09094C-18B8-4E7F-9328-97DB62269E9B</gtr:id><gtr:outcomeId>RLkK3bmRJeD0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Tis is a BAC-based transgenic line for the expression of Cre recombinase under the control of Myf5</gtr:description><gtr:id>93464C60-75A2-45AA-ACB9-C86AB1E4D468</gtr:id><gtr:impact>This is the first Myf5-cre expressing line that fully recapitulates the endogenous expression pattern of Myf5</gtr:impact><gtr:outcomeId>9A5EBEFBD2E</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Myf5-Cre transgenic line</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A transgenic line carrying a BAC in which the tTA2 gene is expressed under the control of Mrf4 regulatory elements</gtr:description><gtr:id>CD25DE84-6907-45AF-ADCE-9FEEB577C8B4</gtr:id><gtr:impact>Work in progress.</gtr:impact><gtr:outcomeId>pTWgJbKAhie</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mrf4-tTA transgenic line</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>394635C4-3F61-4700-B2D3-C744F382D601</gtr:id><gtr:title>Members of the TEAD family of transcription factors regulate the expression of Myf5 in ventral somitic compartments.</gtr:title><gtr:parentPublicationTitle>Developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc466a53c1703c4929d439a72c9fa8c8"><gtr:id>dc466a53c1703c4929d439a72c9fa8c8</gtr:id><gtr:otherNames>Ribas R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0012-1606</gtr:issn><gtr:outcomeId>AE97XFGikPi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C21F95B2-0957-4D16-8F99-B7EC44A2B790</gtr:id><gtr:title>A novel Gli3 enhancer controls the Gli3 spatiotemporal expression pattern through a TALE homeodomain protein binding site.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5adedec82d804278d3490d2f3709f7e6"><gtr:id>5adedec82d804278d3490d2f3709f7e6</gtr:id><gtr:otherNames>Coy S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn><gtr:outcomeId>pm_540e13ce13c64dbea</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D74273FB-20B8-4DBF-899D-5049FBB98DB9</gtr:id><gtr:title>Global transcriptional regulation of the locus encoding the skeletal muscle determination genes Mrf4 and Myf5.</gtr:title><gtr:parentPublicationTitle>Genes &amp; development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eec5c2906cd7823a259097e3eb2af700"><gtr:id>eec5c2906cd7823a259097e3eb2af700</gtr:id><gtr:otherNames>Carvajal JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0890-9369</gtr:issn><gtr:outcomeId>7C134C841A0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02077750-5B8C-42F7-BA0A-EA901776D172</gtr:id><gtr:title>Musculin and TCF21 coordinate the maintenance of myogenic regulatory factor expression levels during mouse craniofacial development.</gtr:title><gtr:parentPublicationTitle>Development (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59dcc93c1bc58003451c6220a392fc69"><gtr:id>59dcc93c1bc58003451c6220a392fc69</gtr:id><gtr:otherNames>Moncaut N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0950-1991</gtr:issn><gtr:outcomeId>AzHySNBTnk6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E708144-0B50-4B89-931F-0C2EBB6F7536</gtr:id><gtr:title>The myogenic factor Myf5 supports efficient skeletal muscle regeneration by enabling transient myoblast amplification.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fb7ac9d1a67601b233dbe6d21ffd100"><gtr:id>0fb7ac9d1a67601b233dbe6d21ffd100</gtr:id><gtr:otherNames>Ustanina S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>F6CF1A5D796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDA5C83A-BD00-4ED6-96E5-3579DC781A00</gtr:id><gtr:title>Mrf4 (myf6) is dynamically expressed in differentiated zebrafish skeletal muscle.</gtr:title><gtr:parentPublicationTitle>Gene expression patterns : GEP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7668c0db94e14ce49cdca150f128367c"><gtr:id>7668c0db94e14ce49cdca150f128367c</gtr:id><gtr:otherNames>Hinits Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1567-133X</gtr:issn><gtr:outcomeId>21983BE4B16</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66728651-BA63-442D-9876-F38481945CFF</gtr:id><gtr:title>Transcriptional dominance of Pax7 in adult myogenesis is due to high-affinity recognition of homeodomain motifs.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/851f99d8d8a26cbacefa76f9ec231af9"><gtr:id>851f99d8d8a26cbacefa76f9ec231af9</gtr:id><gtr:otherNames>Soleimani VD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn><gtr:outcomeId>mP477SZ3DFk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F84BC5A-023D-48A9-9389-C07949E57F93</gtr:id><gtr:title>Critical role of FLRT1 phosphorylation in the interdependent regulation of FLRT1 function and FGF receptor signalling.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac782ebc494f38ee56ce8275753b1d63"><gtr:id>ac782ebc494f38ee56ce8275753b1d63</gtr:id><gtr:otherNames>Wheldon LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>CvsjtBmL9nS</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0401199</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>